A joint project of the Graduate School, Peabody College, and the Jean & Alexander Heard Library

Title page for ETD etd-03182017-172104

Type of Document Dissertation
Author Gallant, Jean-Nicolas
URN etd-03182017-172104
Title EGFR Rearrangements as Oncogenic Drivers and Therapeutic Targets in Lung Cancer
Degree PhD
Department Cancer Biology
Advisory Committee
Advisor Name Title
Christopher Williams Committee Chair
Christine Lovly Committee Member
Rebecca Cook Committee Member
Robert Coffey Committee Member
Sally York Committee Member
  • targeted therapy
  • EGFR
  • gene rearrangement
  • gene fusion
  • lung cancer
  • translational medicine
  • structural biology
  • personalized medicine
Date of Defense 2017-02-28
Availability unrestricted
Lung cancer is the leading cause of cancer deaths worldwide. More than 40% of lung cancers are classified as lung adenocarcinoma (LUAD), which is defined by pathological characteristics. Oncogenic mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain (TKD) are found in a significant portion of LUAD. Such mutations, which present most commonly as small in-frame deletions in exon 19 (ex19del) or as point mutations in exon 21 (L858R), allow for EGFR activation, sensitivity to EGFR tyrosine kinase inhibitors (TKIs), and molecularly targeted therapy in this malignancy.

By analyzing the tumors of patients with LUAD, we identified two EGFR alterations that had not previously been reported in lung cancer: the EGFR kinase domain duplication (EGFR-KDD) and the EGFR-RAD51 fusion. While knowledge about common EGFR mutations (L858R or ex19del) has allowed for rational treatment of specific cohorts of LUAD, nothing was known about the EGFR-KDD and EGFR-RAD51 in LUAD. These mutations—which we call EGFR rearrangements—maintain the wild type sequence of the EGFR TKD and could have mediated either sensitivity or primary resistance to EGFR-TKI therapy. The goal of these studies was to fill in this knowledge gap: to characterize a new type of EGFR alteration in LUAD, to determine the sensitivity of these rearrangements to therapy, and, along the way, to uncover more about the biology of EGFR.

Collectively, the research in this dissertation used in vitro and in silico models, as well as patient-derived data, to address a previously unrecognized potential mechanism of oncogenesis in lung cancer: EGFR rearrangements. These studies established EGFR-KDD and EGFR-RAD51 as bona fide recurrent oncogenes and therapeutic targets in LUAD. The work is already proving clinically relevant as these alterations have been identified in additional lung cancer patients—who may now have more targeted treatment options.

  Filename       Size       Approximate Download Time (Hours:Minutes:Seconds) 
 28.8 Modem   56K Modem   ISDN (64 Kb)   ISDN (128 Kb)   Higher-speed Access 
  jGallant.pdf 39.65 Mb 03:03:33 01:34:24 01:22:36 00:41:18 00:03:31

Browse All Available ETDs by ( Author | Department )

If you have more questions or technical problems, please Contact LITS.